Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. No Oxular employees are joining Regeneron, though several will be “helping short-term with tech transfer and transition work in consulting roles,”. The company had about 20 employees at the time of acquisition, according to LinkedIn. Source: Fierce Biotech 2/1/2025